TY - CHAP M1 - Book, Section TI - Subcutaneous amivantamab with lazertinib is non-inferior to intravenous administration, with fewer adverse reactions A1 - Giuliano, Vanessa A1 - Chan, Sze Wah Samuel PY - 2015 T2 - 2 Minute Medicine AB - SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/10/06 UR - accessmedicine.mhmedical.com/updatesContent.aspx?gbosid=649041 ER -